Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

The XPD Lys751Gln Polymorphism has Predictive Value in Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Systemic Review and Meta-analysis

  • Qian, Ying-Ying (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Xin-You (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) ;
  • Pei, Dong (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Xu, Jia-Li (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Shen, Hua (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Chen, Xiao-Feng (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Yi-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Shen, Li-Zong (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) ;
  • Shu, Yong-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The predictive value of the xeroderma pigmentosum group D (XPD) Lys751Gln polymorphism regarding clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, but the results remain inconclusive. Therefore, we performed a meta-analysis to determine the precise role of the XPD Lys751Gln polymorphism in this clinical situation and optimize individual chemotherapy. Materials and Methods: A multiple search strategy was used to identify eligible studies. Pooled odds ratios (ORs), generalized odds ratio (ORG) and their 95% confidence intervals (CIs) were used to estimate the objective response, while hazard ratios (HRs) with 95%CIs were used for progression-free survival (PFS) and overall survival (OS). Results: A total of 17 studies including 2,286 patients met the inclusion criteria. Overall, the XPD 751Gln allele was associated with a non-significant reduced objective response to oxaliplatin-based chemotherapy in all patients or in the Asian and Caucasian subgroups. However, poor PFS and OS of CRC patients treated with oxaliplatin-based regimens were significantly related to the XPD 751Gln allele in the dominant model (PFS: HR=2.10, 95%CI: 1.65-2.67; OS: HR=3.18, 95%CI: 1.57-6.47). On stratified analysis by ethnicity, these relationships were more pronounced in Asians (PFS: HR=2.49, 95%CI: 1.79-3.47; OS: HR=5.25, 95%CI: 3.46-7.94) than in Caucasians (PFS: HR=1.73, 95%CI: 1.22-2.46; OS: HR=1.78, 95%CI: 1.06-2.99). Conclusions: The XPD Lys751Gln polymorphism may have prognostic value in patients with CRC undergoing oxaliplatin-based chemotherapy.

Keywords

References

  1. Ahmad S (2010). Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers, 7, 543-66. https://doi.org/10.1002/cbdv.200800340
  2. Altman DG, Bland JM (2003). Interaction revisited: the difference between two estimates. BMJ, 326, 219. https://doi.org/10.1136/bmj.326.7382.219
  3. Balboa E, Duran G, Lamas MJ, et al (2010). Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics, 11, 747-61. https://doi.org/10.2217/pgs.10.51
  4. Boige V, Mendiboure J, Pignon JP, et al (2010). Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol, 28, 2556-64. https://doi.org/10.1200/JCO.2009.25.2106
  5. Chen YC, Tzeng CH, Chen PM, et al (2010). Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci, 101, 530-5. https://doi.org/10.1111/j.1349-7006.2009.01418.x
  6. Chen YM, Wu XL, Zhang LW, et al (2012). Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients. Zhonghua Zhong Liu Za Zhi, 34, 501-5 (in Chinese).
  7. Dybdahl M, Vogel U, Frentz G, et al (1999). Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev, 8, 77-81.
  8. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, et al (2010). Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol, 69, 58-66. https://doi.org/10.1111/j.1365-2125.2009.03556.x
  9. Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37. https://doi.org/10.1016/S0006-2952(03)00260-0
  10. Farina Sarasqueta A, van Lijnschoten G, Lemmens VE, et al (2011). Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol Diagn Ther, 15, 277-83. https://doi.org/10.1007/BF03256419
  11. Fuss JO, Tainer JA (2011). XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. DNA Repair (Amst), 10, 697-713. https://doi.org/10.1016/j.dnarep.2011.04.028
  12. Gan Y, Li X-R, Chen D-J, et al (2012). Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a chinese population. Asian Pac J Cancer Prev, 13, 5721-4. https://doi.org/10.7314/APJCP.2012.13.11.5721
  13. Haller DG, Tabernero J, Maroun J, et al (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol, 29, 1465-71. https://doi.org/10.1200/JCO.2010.33.6297
  14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  15. Kang S, Sun HY, Zhou RM, et al (2013). DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy. Asian Pac J Cancer Prev, 14, 941-6. https://doi.org/10.7314/APJCP.2013.14.2.941
  16. Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer, 8, 148. https://doi.org/10.1186/1471-2407-8-148
  17. Kuebler JP, Wieand HS, O'Connell MJ, et al (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 25, 2198-204. https://doi.org/10.1200/JCO.2006.08.2974
  18. Kumamoto K, Ishibashi K, Okada N, et al (2013). Polymorphisms of , and -3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett, 6, 648-54.
  19. Lai JI, Tzeng CH, Chen PM, et al (2009). Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci, 100, 1261-6. https://doi.org/10.1111/j.1349-7006.2009.01186.x
  20. Lamas MJ, Duran G, Balboa E, et al (2011). Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 12, 433-42. https://doi.org/10.2217/pgs.10.196
  21. Le Morvan V, Smith D, Laurand A, et al (2007). Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics, 8, 1693-703. https://doi.org/10.2217/14622416.8.12.1693
  22. Lee KH, Chang HJ, Han SW, et al (2013). Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol, 71, 843-51. https://doi.org/10.1007/s00280-013-2075-3
  23. Leichman LP, Goldman BH, Bohanes PO, et al (2011). S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol, 29, 4555-60. https://doi.org/10.1200/JCO.2011.36.7490
  24. Li H-Y, Ge X, Huang G-M, et al (2012). GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population. Asian Pac J Cancer Prev, 13, 3465-9. https://doi.org/10.7314/APJCP.2012.13.7.3465
  25. Lunn RM, Helzlsouer KJ, Parshad R, et al (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis, 21, 551-5. https://doi.org/10.1093/carcin/21.4.551
  26. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5. https://doi.org/10.1158/1078-0432.CCR-07-2238
  27. Martinez-Balibrea E, Abad A, Aranda E, et al (2008). Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer, 44, 1229-37. https://doi.org/10.1016/j.ejca.2008.03.025
  28. McLeod HL, Sargent DJ, Marsh S, et al (2010). Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol, 28, 3227-33. https://doi.org/10.1200/JCO.2009.21.7943
  29. Monzo M, Moreno I, Navarro A, et al (2007). Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology, 72, 364-70. https://doi.org/10.1159/000113534
  30. Moreno V, Gemignani F, Landi S, et al (2006). Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res, 12, 2101-8. https://doi.org/10.1158/1078-0432.CCR-05-1363
  31. Pare L, Marcuello E, Altes A, et al (2008). Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer, 99, 1050-5. https://doi.org/10.1038/sj.bjc.6604671
  32. Park DJ, Stoehlmacher J, Zhang W, et al (2001). A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res, 61, 8654-8.
  33. Ruzzo A, Graziano F, Loupakis F, et al (2007). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol, 25, 1247-54. https://doi.org/10.1200/JCO.2006.08.1844
  34. Spitz MR, Wu X, Wang Y, et al (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res, 61, 1354-7.
  35. Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
  36. Sun XH, Hou WG, Zhao HX, et al (2013). Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Asian Pac J Cancer Prev, 14, 2049-52. https://doi.org/10.7314/APJCP.2013.14.3.2049
  37. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  38. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  39. Wang LE, Gorlova OY, Ying J, et al (2013). Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. Cancer Res, 73, 256-64.
  40. Wolfe KJ, Wickliffe JK, Hill CE, et al (2007). Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics, 17, 897-905. https://doi.org/10.1097/FPC.0b013e3280115e63
  41. Yin M, Yan J, Martinez-Balibrea E, et al (2011). ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res, 17, 1632-40. https://doi.org/10.1158/1078-0432.CCR-10-2169
  42. Yu YJ, Li YM, Hou XD, et al (2012). Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell. Asian Pac J Cancer Prev, 13, 1845-9. https://doi.org/10.7314/APJCP.2012.13.5.1845
  43. Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. https://doi.org/10.7314/APJCP.2012.13.6.2583
  44. Zintzaras E (2010). The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol, 9, 21.

Cited by

  1. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction vol.76, pp.6, 2015, https://doi.org/10.1007/s00280-015-2872-y
  2. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients vol.17, pp.7, 2016, https://doi.org/10.2217/pgs-2015-0017